After publication of this article [1] it was noticed there were errors in the paper regarding the dose and grade of glucosyl hesperidin due to miscommunications.
Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial The composition of glucosyl hesperidin is reported as "500 mg" but this should instead be listed as "470 mg" throughout the article. Additionally, the G-hesperidin should be reported as containing 74% monoglucosyl hesperidin and residual non-glycosylated hesperidin. 
